<div id="readability-page-1"><p>Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Connect Biopharma in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($1.04) per share for the year, down from their prior estimate of ($0.90). HC Wainwright has a &#34;Buy&#34; rating and a $7.00 price target on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma's Q4 2025 earnings at ($0.32) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.97) EPS, FY2028 earnings at ($0.80) EPS and FY2029 earnings at ($0.53) EPS.</p><div><p><span></span><span>Get <strong>Connect Biopharma</strong> alerts:</span></p></div><p>Connect Biopharma (NASDAQ:CNTB - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.07). </p><p>CNTB has been the subject of several other research reports. BTIG Research  reaffirmed a &#34;buy&#34; rating and set a $10.00 price objective on shares of Connect Biopharma in a research note on Thursday. Northland Capmk raised shares of Connect Biopharma to a &#34;strong-buy&#34; rating in a report on Tuesday, July 22nd. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Connect Biopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Connect Biopharma to a &#34;hold&#34; rating in a research report on Friday, August 22nd. One investment analyst  has rated the stock with a Strong Buy rating, two have given a Buy rating and one  has issued  a Sell rating to the stock. According to MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $8.50.</p><p><b>View Our Latest Stock Report on CNTB</b></p><h2>Connect Biopharma Stock Up 26.2%</h2><p>Shares of NASDAQ CNTB opened at $2.12 on Monday. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01. The company has a market cap of $118.52 million, a P/E ratio of -5.05 and a beta of -0.14. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $2.86. The business has a 50-day simple moving average of $1.66 and a two-hundred day simple moving average of $1.47. </p><h2>Institutional Trading of Connect Biopharma</h2><p>Several hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in  Connect Biopharma during the second quarter valued at about $29,000.  AlphaCore Capital LLC bought a new stake in shares of  Connect Biopharma in the 2nd quarter valued at about $78,000.  Finally, Koa Wealth Management LLC bought a new stake in shares of  Connect Biopharma in the 2nd quarter valued at about $49,000. 58.72% of the stock is owned by institutional investors. </p><h2>Connect Biopharma Company Profile</h2> (Get Free Report)<p>Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.</p><h2>See Also</h2><ul><li>Five stocks we like better than Connect Biopharma</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li><li>What is the NASDAQ Stock Exchange?</li><li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li><li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Connect Biopharma Right Now?</h2><p>Before you consider Connect Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.</p><p>While Connect Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTB

<p>HC Wainwright has lowered its FY2025 EPS estimates for Connect Biopharma to ($1.04) from ($0.90), maintaining a "Buy" rating with a $7.00 price target. The stock has a Moderate Buy consensus with a target price of $8.50. Connect Biopharma's shares rose 26.2% to $2.12. Institutional investors own 58.72% of the stock. The company focuses on therapies for T cell-driven inflammatory diseases.</p>

HC Wainwright Issues Pessimistic Estimate for CNTB Earnings